CSIMarket Company Name, Ticker, Industry, else..
 
Rafael Holdings Inc  (NYSE: RFL)
 
Price: $2.5600 $0.09 3.644%
Day's High: $2.740000009536743 Week Perf: -0.39 %
Day's Low: $ 2.49 30 Day Perf: 26.73 %
Volume (M): 138,500 52 Wk High: $ 3.96
Volume (M$): $ 0 52 Wk Avg: $1.55
Open: $2.49 52 Wk Low: $1.12



 Market Capitalization (Millions $) 131
 Shares Outstanding (Millions) 51
 Employees 23
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) 28
 Cash Flow (TTM) (Millions $) 22
 Capital Exp. (TTM) (Millions $) 0

Business Description


Rafael Holdings Inc is a diversified company that owns and operates real estate properties and invests in healthcare assets. It is a subsidiary of IDT Corporation, a multinational holding company. Rafael Holdings primarily focuses on the ownership and management of real estate properties, specializing in commercial and residential spaces. The company also holds a stake in Rafael Pharmaceuticals, a clinical-stage cancer metabolism-based therapeutics company. Overall, Rafael Holdings Inc aims to generate revenue through its real estate properties and investment portfolio.


   Company Address: 520 Broad Street Newark 7102 NJ
   Company Phone Number: 658-1450   Stock Exchange / Ticker: NYSE RFL


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CPRX        0.06% 
KALA   -26.52%    
VNDA        2.65% 
• View Complete Report
   



Clinical Study

Preliminary Data on Trappsol Cyclo and Rafael Holdings Revenue Performance in Q1 2025 A Comparative Analysis

Published Tue, Sep 16 2025 12:49 PM UTC

: This article presents an analysis of the recent preliminary data concerning the Phase 3 open-label sub-study evaluating Trappsol Cyclo (hydroxypropyl-beta-cyclodextrin) for the treatment of Niemann-Pick disease type C1 (NPC1) in patients under three years old, as well as an overview of Rafael Holdings, Inc. s financial performance in the first quarter of 2025 relative to...
Management Changes

Rafael Holdings Realigns Focus on Trappsol Cyclo Amid Leadership Changes and Significant Clinical Trial Milestone

Published Thu, Apr 24 2025 8:15 PM UTC

In an era where the advancement of medical treatments for rare diseases is of paramount importance, Rafael Holdings has reaffirmed its commitment to the development of Trappsol Cyclo, a promising investigational drug for Niemann-Pick Disease Type C1 (NPC1). This milestone announcement comes alongside notable leadership changes as chief executive officer Bill Conkling prepare...
Merger and Acquisition

Cyclo Therapeutics Phase 3 Trial for Trappsol Cyclo in Niemann-Pick Disease Type C1 Fully Enrolled; Interim Results Expected Mid-2025

Published Wed, Mar 26 2025 10:50 AM UTC

Breaking News Cyclo Therapeutics’ Phase 3 Clinical Trial for Niemann-Pick Disease Type C1 Fully Enrolled, Interim Analysis Results Anticipated in 2025City, State – In a groundbreaking development for patients suffering from Niemann-Pick Disease Type C1, Cyclo Therapeutics announced that the Phase 3 clinical trial for their investigational treatment, Trappsol Cyclo, has r...
Merger and Acquisition

Rafael Holdings: Merging Paths and Financial Foundations Analyzing Q2 Fiscal 2025 and Beyond

Published Thu, Mar 13 2025 9:51 PM UTC

In a notable update for investors and stakeholders, Rafael Holdings, Inc. (NYSE: RFL) has reported its financial results for the second quarter of fiscal 2025, during which the company showcased its diverse portfolio and strategic initiatives. With a current market capitalization of approximately $24 million, Rafael Holdings operates as a diversified holding company with inv...
Merger and Acquisition

A Strategic Union: Rafael Holdings and Cyclo Therapeutics Set to Navigate New Frontiers in Rare Disease Treatment

Published Thu, Aug 22 2024 10:50 AM UTC




In a significant development that promises to reshape the landscape of rare disease treatment, Rafael Holdings (NYSE: RFL) has entered into a definitive merger agreement with Cyclo Therapeutics. This strategic partnership is poised to leverage Rafael s investment capabilities and Cyclo s innovative approaches to pharmaceutical research, particularly with their...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 115.96
Price to Sales (Expected) -
Price to Book 1.62
PEG (TTM) -

Financial Strength Current
Quick Ratio 2.79
Working Capital Ratio 3.18
Leverage Ratio (MRQ) 0.2
Total Debt to Equity 0.01
Interest Coverage (TTM) -
Debt Coverage (TTM) 41.2

Per Share Current
Earnings (TTM) -0.47 $
Revenues (TTM) 0.02 $
Cash Flow (TTM) 0.44 $
Cash 0.6 $
Book Value 1.58 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 49,174
Net Income per Employee (TTM) 1,224,609
Receivable Turnover Ratio (TTM) 2.59
Inventory Turnover Ratio (TTM) 0.72
Asset Turnover Ratio (TTM) 0.01

Profitability Ratios Current
Gross Margin (MRQ) 95.53 %
Operating Margin (MRQ) -3837.99 %
Net Margin (MRQ) -1618.99 %
Net Cash Flow Margin (MRQ) -8403.35 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) 26.77 %
Return On Investment (TTM) 28.76 %
Return On Equity (TTM) 31.93 %
Dividend Yield -
Pay out Ratio (TTM) -



Rafael Holdings Inc's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.